Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
<1m ago PERNOD RICARD : USA :, JP Wiser's Launch Program Aimed at Reducing Drunk Driving
<1m ago NATIONAL : Document Security Systems Commences Registered Direct Offering of Common Stock
<1m ago RICE MIDSTREAM PARTNERS LP : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
1m ago F N B : FNB CORP/FL/ : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Financial Statements and Exhibits (form 8-K)
1m ago CANCANA RESOURCES : Announces Disposition of MLB Mining Claims, Execution of Shareholders' Agreement and US$1.5 Million Convertible Debenture Financing
1m ago FIVE BELOW : Change in Directors or Principal Officers (form 8-K)
1m ago BANK OF KENTUCKY FINANCIAL : Other Events, Financial Statements and Exhibits (form 8-K)
1m ago LIGE VAL : LIGHTSTONE VALUE PLUS REAL ESTATE INVESTMENT TRUST II INC : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)
1m ago FIBRIA CELULOSE : Minutes of the Meeting of the Board of Directors
1m ago WATERSTONE FINANCIAL : Declares Regular Quarterly Cash Dividend
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : Wearable tech on 1 in 3 Christmas wish lists, experts predicting 17 million to own it within three years
PETARDS : Wins GBP1 Million Equipment Deal With Ministry Of Defence
SOITEC : updates its 2015 and 2016 financial guidance
ChinaNet Online Holdings Signs Strategic Partnership Agreement With MediaFun
OCWEN FINANCIAL : Agrees to Settlement With New York Dept. of Financial Services
Most Read News
1d ago GOODMAN : GMG distribution for the six months ending 31 December 2014
4h ago DAVIDE CAMPARI MILANO : Sale of Limoncetta di Sorrento in Italy and sale of the Federated Pharmaceutical division in Jamaica
4h ago ADHERE CREATIVE : Named 'Platinum Partner' by Renowned Marketing Company HubSpot
4h agoDJAlstom to Pay $772 Million to Settle Bribery Charges -- 2nd Update
4h ago BLOOMSBURY PUBLISHING : Acquisition of Osprey Publishing Limited
Most recommended articles
7m ago WALL STREET STOCK EXCHANGE : China's shadow banking adapts and grows as rules tighten
13m ago TSX ends lower as resource stocks decline
14m ago Wall Street up for fourth day; energy falls again
17m agoDJOracle Agrees to Buy Datalogix Holdings--Update
20m ago British Pound Vulnerable on Fading Rate Hike Outlook
Dynamic quotes  
ON
| OFF